New scan for high-grade neuroendocrine cancer
Part of Cancer clinical trials.
This trial tests a new type of PET/CT scan called [68Ga]Ga-FAPI-04 to see if it can better detect high-grade neuroendocrine tumors. It is for patients whose standard scans show low uptake or who have aggressive tumor features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a neuroendocrine tumor that is high-grade (aggressive)
- Your past DOTATATE scan showed low uptake, or your Krenning Score is 3 or higher, or your Ki67 index is 20% or more
- You can lie flat for 60 minutes
- You are not pregnant or breastfeeding
- You have not had surgery recently with a healing wound
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how useful a specific scan (68Ga-DOTA-TATE PET/CT) is for tumors that have certain “targets” (somatostatin receptors). It may help doctors better identify and guide care for neuroendocrine tumors.
This early-phase study tests whether a special scan using 68Ga-HA-DOTATATE can help identify or diagnose tumors that have “somatostatin receptors.” It also checks how safe this scanning approach is and whether it provides useful information for people who may have these tumor types.
This trial tests a new type of PET scan using a radioactive tracer called 61Cu-NODAGA-LM3 to detect neuroendocrine tumors (NETs). The goal is to see if it works as well as or better than the standard scan. If you have a NET and need a scan for staging or treatment planning, you might be able to join.
This trial tests a new type of PET/CT scan that uses a special tracer (called ⁶⁸Ga-FXX489) to help find and diagnose cancers. It is for people who are strongly suspected to have cancer and want to see if this new imaging method can help their doctors learn more about their disease.
This trial uses a special PET scan to see how well it can find and track different types of cancer. It may help doctors better understand your cancer.
This trial tests a PET scan (a type of imaging) that targets cells in the body that help support cancers. It may help doctors better see where cancer-associated cells are located, which could guide future cancer care.
Hear when a new Neuroendocrine Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.